Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy

Objectives: Bladder cancer is a heterogeneous malignancy. Therefore, it is difficult to find single predictive markers. Moreover, most studies focus on either the immunohistochemical or molecular assessment of tumor tissues by next-generation sequencing (NGS) or PCR, while a combination of immunohis...

Full description

Bibliographic Details
Main Authors: Thorsten H. Ecke, Adisch Kiani, Thorsten Schlomm, Frank Friedersdorff, Anja Rabien, Klaus Jung, Ergin Kilic, Peter Boström, Minna Tervahartiala, Pekka Taimen, Jan Gleichenhagen, Georg Johnen, Thomas Brüning, Stefan Koch, Jenny Roggisch, Ralph M. Wirtz
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/19/7420
id doaj-b4bd8dd4ff7c4bb5b21b715d3faf9cb4
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Thorsten H. Ecke
Adisch Kiani
Thorsten Schlomm
Frank Friedersdorff
Anja Rabien
Klaus Jung
Ergin Kilic
Peter Boström
Minna Tervahartiala
Pekka Taimen
Jan Gleichenhagen
Georg Johnen
Thomas Brüning
Stefan Koch
Jenny Roggisch
Ralph M. Wirtz
spellingShingle Thorsten H. Ecke
Adisch Kiani
Thorsten Schlomm
Frank Friedersdorff
Anja Rabien
Klaus Jung
Ergin Kilic
Peter Boström
Minna Tervahartiala
Pekka Taimen
Jan Gleichenhagen
Georg Johnen
Thomas Brüning
Stefan Koch
Jenny Roggisch
Ralph M. Wirtz
Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
International Journal of Molecular Sciences
survivin
BIRC5
macrophage
KRT20
ERBB2
MIBC
author_facet Thorsten H. Ecke
Adisch Kiani
Thorsten Schlomm
Frank Friedersdorff
Anja Rabien
Klaus Jung
Ergin Kilic
Peter Boström
Minna Tervahartiala
Pekka Taimen
Jan Gleichenhagen
Georg Johnen
Thomas Brüning
Stefan Koch
Jenny Roggisch
Ralph M. Wirtz
author_sort Thorsten H. Ecke
title Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
title_short Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
title_full Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
title_fullStr Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
title_full_unstemmed Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
title_sort prognostic role of survivin and macrophage infiltration quantified on protein and mrna level in molecular subtypes determined by rt-qpcr of <i>krt5</i>, <i>krt20</i>, and <i>erbb2</i> in muscle-invasive bladder cancer treated by adjuvant chemotherapy
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-10-01
description Objectives: Bladder cancer is a heterogeneous malignancy. Therefore, it is difficult to find single predictive markers. Moreover, most studies focus on either the immunohistochemical or molecular assessment of tumor tissues by next-generation sequencing (NGS) or PCR, while a combination of immunohistochemistry (IHC) and PCR for tumor marker assessment might have the strongest impact to predict outcome and select optimal therapies in real-world application. We investigated the role of proliferation survivin/<i>BIRC5</i> and macrophage infiltration (CD68, MAC387, CLEVER-1) on the basis of molecular subtypes of bladder cancer (KRT5, KRT20, ERBB2) to predict outcomes of adjuvant treated muscle-invasive bladder cancer patients with regard to progression-free survival (PFS) and disease-specific survival (DSS). Materials and Methods: We used tissue microarrays (TMA) from n = 50 patients (38 males, 12 female) with muscle-invasive bladder cancer. All patients had been treated with radical cystectomy followed by adjuvant triple chemotherapy. Median follow-up time was 60.5 months. CD68, CLEVER-1, MAC387, and survivin protein were detected by immunostaining and subsequent visual inspection. <i>BIRC5</i>, <i>KRT5</i>, <i>KRT20</i>, <i>ERBB2</i>, and <i>CD68</i> mRNAs were detected by standardized RT-qPCR after tissue dot RNA extraction using a novel stamp technology. All these markers were evaluated in three different centers of excellence. Results: Nuclear staining rather than cytoplasmic staining of survivin predicted DSS as a single marker with high levels of survivin being associated with better PFS and DSS upon adjuvant chemotherapy (<i>p</i> = 0.0138 and <i>p</i> = 0.001, respectively). These results were validated by the quantitation of <i>BIRC5</i> mRNA by PCR (<i>p</i> = 0.0004 and <i>p</i> = 0.0508, respectively). Interestingly, nuclear staining of survivin protein was positively associated with <i>BIRC5</i> mRNA, while cytoplasmic staining was inversely related, indicating that the translocation of survivin protein into the nucleus occurred at a discrete, higher level of its mRNA. Combining survivin/<i>BIRC5</i> levels based on molecular subtype being assessed by <i>KRT20</i> expression improved the predictive value, with tumors having low survivin/<i>BIRC5</i> and <i>KRT20</i> mRNA levels having the best survival (75% vs. 20% vs. 10% 5-year DSS, <i>p</i> = 0.0005), and these values were independent of grading, node status, and tumor stage in multivariate analysis (<i>p</i> = 0.0167). Macrophage infiltration dominated in basal tumors and was inversely related with the luminal subtype marker gene expression. The presence of macrophages in survivin-positive or <i>ERBB2</i>-positive tumors was associated with worse DSS. Conclusions: For muscle-invasive bladder cancer patients, the proliferative activity as determined by the nuclear staining of survivin or RT-qPCR on the basis of molecular subtype characteristics outperforms single marker detections and single technology approaches. Infiltration by macrophages detected by IHC or PCR is associated with worse outcome in defined subsets of tumors. The limitations of this study are the retrospective nature and the limited number of patients. However, the number of molecular markers has been restricted and based on predefined assumptions, which resulted in the dissection of muscle-invasive disease into tumor–biological axes of high prognostic relevance, which warrant further investigation and validation.
topic survivin
BIRC5
macrophage
KRT20
ERBB2
MIBC
url https://www.mdpi.com/1422-0067/21/19/7420
work_keys_str_mv AT thorstenhecke prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT adischkiani prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT thorstenschlomm prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT frankfriedersdorff prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT anjarabien prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT klausjung prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT erginkilic prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT peterbostrom prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT minnatervahartiala prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT pekkataimen prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT jangleichenhagen prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT georgjohnen prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT thomasbruning prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT stefankoch prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT jennyroggisch prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
AT ralphmwirtz prognosticroleofsurvivinandmacrophageinfiltrationquantifiedonproteinandmrnalevelinmolecularsubtypesdeterminedbyrtqpcrofikrt5iikrt20iandierbb2iinmuscleinvasivebladdercancertreatedbyadjuvantchemotherapy
_version_ 1724510928737665024
spelling doaj-b4bd8dd4ff7c4bb5b21b715d3faf9cb42020-11-25T03:45:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-01217420742010.3390/ijms21197420Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant ChemotherapyThorsten H. Ecke0Adisch Kiani1Thorsten Schlomm2Frank Friedersdorff3Anja Rabien4Klaus Jung5Ergin Kilic6Peter Boström7Minna Tervahartiala8Pekka Taimen9Jan Gleichenhagen10Georg Johnen11Thomas Brüning12Stefan Koch13Jenny Roggisch14Ralph M. Wirtz15Department of Urology, HELIOS Hospital Bad Saarow, DE-15526 Bad Sarrow, GermanyDepartment of Urology, Charité—Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, GermanyDepartment of Urology, Charité—Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, GermanyDepartment of Urology, Charité—Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, GermanyDepartment of Urology, Charité—Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, GermanyDepartment of Urology, Charité—Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, GermanyInstitute of Pathology, DE-51375 Leverkusen, GermanyDepartment of Urology, Turku University Hospital, FI-20521 Turku, FinlandMediCity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, FI-20520 Turku, FinlandInstitute of Pathology, Turku University Hospital, FI-20521 Turku, FinlandInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, DE-44789 Bochum, GermanyInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, DE-44789 Bochum, GermanyInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, DE-44789 Bochum, GermanyBrandenburg Medical School, DE-14770 Brandenburg, GermanyInstitute of Pathology, HELIOS Hospital Bad Saarow, DE-15526 Bad Sarrow, GermanySTRATIFYER Molecular Pathology GmbH, DE-50935 Cologne, GermanyObjectives: Bladder cancer is a heterogeneous malignancy. Therefore, it is difficult to find single predictive markers. Moreover, most studies focus on either the immunohistochemical or molecular assessment of tumor tissues by next-generation sequencing (NGS) or PCR, while a combination of immunohistochemistry (IHC) and PCR for tumor marker assessment might have the strongest impact to predict outcome and select optimal therapies in real-world application. We investigated the role of proliferation survivin/<i>BIRC5</i> and macrophage infiltration (CD68, MAC387, CLEVER-1) on the basis of molecular subtypes of bladder cancer (KRT5, KRT20, ERBB2) to predict outcomes of adjuvant treated muscle-invasive bladder cancer patients with regard to progression-free survival (PFS) and disease-specific survival (DSS). Materials and Methods: We used tissue microarrays (TMA) from n = 50 patients (38 males, 12 female) with muscle-invasive bladder cancer. All patients had been treated with radical cystectomy followed by adjuvant triple chemotherapy. Median follow-up time was 60.5 months. CD68, CLEVER-1, MAC387, and survivin protein were detected by immunostaining and subsequent visual inspection. <i>BIRC5</i>, <i>KRT5</i>, <i>KRT20</i>, <i>ERBB2</i>, and <i>CD68</i> mRNAs were detected by standardized RT-qPCR after tissue dot RNA extraction using a novel stamp technology. All these markers were evaluated in three different centers of excellence. Results: Nuclear staining rather than cytoplasmic staining of survivin predicted DSS as a single marker with high levels of survivin being associated with better PFS and DSS upon adjuvant chemotherapy (<i>p</i> = 0.0138 and <i>p</i> = 0.001, respectively). These results were validated by the quantitation of <i>BIRC5</i> mRNA by PCR (<i>p</i> = 0.0004 and <i>p</i> = 0.0508, respectively). Interestingly, nuclear staining of survivin protein was positively associated with <i>BIRC5</i> mRNA, while cytoplasmic staining was inversely related, indicating that the translocation of survivin protein into the nucleus occurred at a discrete, higher level of its mRNA. Combining survivin/<i>BIRC5</i> levels based on molecular subtype being assessed by <i>KRT20</i> expression improved the predictive value, with tumors having low survivin/<i>BIRC5</i> and <i>KRT20</i> mRNA levels having the best survival (75% vs. 20% vs. 10% 5-year DSS, <i>p</i> = 0.0005), and these values were independent of grading, node status, and tumor stage in multivariate analysis (<i>p</i> = 0.0167). Macrophage infiltration dominated in basal tumors and was inversely related with the luminal subtype marker gene expression. The presence of macrophages in survivin-positive or <i>ERBB2</i>-positive tumors was associated with worse DSS. Conclusions: For muscle-invasive bladder cancer patients, the proliferative activity as determined by the nuclear staining of survivin or RT-qPCR on the basis of molecular subtype characteristics outperforms single marker detections and single technology approaches. Infiltration by macrophages detected by IHC or PCR is associated with worse outcome in defined subsets of tumors. The limitations of this study are the retrospective nature and the limited number of patients. However, the number of molecular markers has been restricted and based on predefined assumptions, which resulted in the dissection of muscle-invasive disease into tumor–biological axes of high prognostic relevance, which warrant further investigation and validation.https://www.mdpi.com/1422-0067/21/19/7420survivinBIRC5macrophageKRT20ERBB2MIBC